The present study aims to investigate whether semaglutide, a long-acting GLP1R agonist, can ameliorate cardiac hypertrophy induced by pressure overload, and explore the potential mechanism
Per the KFF 2025 Employer Health Benefits Survey, 43% of large employer plans (5,000+ employees) cover GLP-1s for weight loss, and virtually all require prior authorization
Today, the official FDA labels for Wegovy and Zepbound continue to warn that there is a risk of suicidal ideation, but the agency clarified in its announcement that the warning is based on evidence from older medicines used or tested for weight loss. Ozempic and Oral Health Keto breath may also explain some cases of Ozempic breath
Extra sharps, alcohol wipes, a thank-you card with a visual injection explainer, and a QR code for more information
semaglutide users at index and at 3, 6, 9, and 12 months post-index (stratified by dosage formulations) for cohort 1, for cohort 2, and overall (cohort 1 and cohort 2) were calculated in France and Italy
By targeting these mechanisms, GLP-1 medications can help patients achieve significant weight loss and manage related metabolic conditions